Please login to the form below

Not currently logged in
Email:
Password:

Valchlor

This page shows the latest Valchlor news and features for those working in and with pharma, biotech and healthcare.

EU nod for Actelion's skin cancer drug Ledaga

EU nod for Actelion's skin cancer drug Ledaga

The Swiss biotech - which already sells Ledaga (mechlorethamine or chlormethine) under the Valchlor brand in the US - notes that the European Commission cleared the drug as a topical treatment for mycosis ... Actelion acquired Valchlor in 2013 when it

Latest news

  • Actelion partners with PatientsLikeMe on blood cancer research Actelion partners with PatientsLikeMe on blood cancer research

    Mitchell Nagao, Actelion's senior director - medical head of Valchlor and Zavesca, said: “ As changes in technology, culture, and treatment affect how patients live with disease, we want measurement to evolve

  • Actelion complete Ceptaris purchase Actelion complete Ceptaris purchase

    Actelion has completed its purchase of Ceptaris Therapeutics following the approval last month of the latter's lymphoma gel product Valchlor. ... Such preparations do not undergo the same rigorous FDA review as Valchlor," he added.

  • Actelion to buy Ceptaris - if FDA backs its cancer treatment Actelion to buy Ceptaris - if FDA backs its cancer treatment

    Acquisition contingent on Valchlor approval in rare lymphoma. Actelion is set to acquire US-based biopharma Ceptaris, but only if US regulators approve Ceptaris' cancer treatment Valchlor. ... Valchlor is also under review in Europe where it is also

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics